This paper evaluates the safety and biodistribution of a novel Nanoligomer targeting SARS-CoV-2 in mice, showing it is safe, nontoxic, and effectively distributed throughout the body.

bioRxiv · Jul 19, 2022Bioengineering

Self-assembling short immunostimulatory duplex RNAs with broad spectrum antiviral activity

L. Si, H. Bai, C. Y. Oh, T. Zhang, A. Jiang, F. Hong, Y. Ye, T. X. Jordan, J. Logue, M. McGrath, C. Belgur, A. Nurani, W. Cao, R. K. Powers, R. Prantil-Baun, , D. E. Ingber

This paper introduces self-assembling short duplex RNAs that induce interferon production and inhibit multiple respiratory viruses.

bioRxiv · Nov 19, 2021Immunology

The FDA-approved drug Alectinib compromises SARS-CoV-2 nucleocapsid phosphorylation and inhibits viral infection in vitro

T. M. Yaron, B. E. Heaton, T. M. Levy, J. L. Johnson, T. X. Jordan, B. M. Cohen, A. Kerelsky, T.-Y. Lin, K. M. Liberatore, D. K. Bulaon, E. R. Kastenhuber, M. N. Mercadante, K. Shobana-Ganesh, L. He, R. E. Schwartz, , M Kavanagh-Williamson

This study identifies Alectinib as an FDA-approved drug that inhibits SARS-CoV-2 nucleocapsid phosphorylation and viral replication in vitro by targeting host kinases.

bioRxiv · Aug 14, 2020 · PreprintMicrobiology